Shobha Dhadda

9.3k total citations · 5 hit papers
70 papers, 5.4k citations indexed

About

Shobha Dhadda is a scholar working on Physiology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Shobha Dhadda has authored 70 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Physiology, 26 papers in Psychiatry and Mental health and 13 papers in Pharmacology. Recurrent topics in Shobha Dhadda's work include Alzheimer's disease research and treatments (33 papers), Dementia and Cognitive Impairment Research (21 papers) and Computational Drug Discovery Methods (12 papers). Shobha Dhadda is often cited by papers focused on Alzheimer's disease research and treatments (33 papers), Dementia and Cognitive Impairment Research (21 papers) and Computational Drug Discovery Methods (12 papers). Shobha Dhadda collaborates with scholars based in United States, United Kingdom and Japan. Shobha Dhadda's co-authors include Lynn D. Kramer, Chad J. Swanson, Larisa Reyderman, Michael C. Irizarry, Michio Kanekiyo, Randall J. Bateman, Michelle Gee, Christopher H. van Dyck, Paul Aisen and Marwan Sabbagh and has published in prestigious journals such as New England Journal of Medicine, Neurology and Annals of Neurology.

In The Last Decade

Shobha Dhadda

63 papers receiving 5.2k citations

Hit Papers

Lecanemab in Early Alzheimer’s Disease 2021 2026 2022 2024 2022 2021 2022 2022 2024 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lecanemab in Early Alzheimer’s Disease
    2022 2.7k citations Christopher H. van Dyck, Chad J. Swanson et al. New England Journal of Medicine profile →
  2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
    2021 580 citations Chad J. Swanson, Shobha Dhadda et al. Alzheimer s Research & Therapy profile →
  3. Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
    2022 185 citations Eric McDade, Jeffrey L. Cummings et al. Alzheimer s Research & Therapy profile →
  4. The AHEAD 3‐45 Study: Design of a prevention trial for Alzheimer's disease
    2022 130 citations Reisa A. Sperling, Michael Donohue et al. Alzheimer s & Dementia profile →
  5. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
    2024 61 citations Lawrence S. Honig, Marwan N. Sabbagh et al. Alzheimer s Research & Therapy profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shobha Dhadda United States 25 2.6k 1.6k 1.1k 893 687 70 5.4k
Larisa Reyderman United States 24 2.2k 0.9× 1.2k 0.8× 817 0.7× 1.2k 1.4× 623 0.9× 107 5.2k
Craig Ritchie United Kingdom 44 2.9k 1.1× 2.4k 1.5× 919 0.8× 1.1k 1.2× 899 1.3× 210 7.7k
Alina Solomon Finland 45 2.9k 1.1× 2.6k 1.6× 557 0.5× 1.2k 1.4× 927 1.3× 174 7.5k
Marwan Sabbagh United States 9 1.9k 0.7× 1.2k 0.7× 536 0.5× 731 0.8× 687 1.0× 14 3.7k
María M. Corrada United States 43 3.1k 1.2× 2.7k 1.6× 702 0.6× 859 1.0× 1.2k 1.7× 171 7.5k
Alireza Atri United States 35 1.7k 0.7× 2.0k 1.2× 727 0.7× 639 0.7× 519 0.8× 119 5.0k
Maria Eriksdotter Sweden 52 3.1k 1.2× 2.6k 1.6× 744 0.7× 1.6k 1.8× 1.2k 1.8× 266 9.4k
Kate Zhong United States 24 2.6k 1.0× 1.4k 0.9× 1.4k 1.3× 1.3k 1.5× 710 1.0× 35 5.4k
Jean‐Marc Orgogozo France 36 2.1k 0.8× 2.4k 1.5× 778 0.7× 751 0.8× 1.4k 2.0× 81 6.6k
Lynn D. Kramer United States 21 2.4k 0.9× 2.1k 1.3× 765 0.7× 927 1.0× 700 1.0× 64 5.0k

Countries citing papers authored by Shobha Dhadda

Since Specialization
Citations

This map shows the geographic impact of Shobha Dhadda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shobha Dhadda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shobha Dhadda more than expected).

Fields of papers citing papers by Shobha Dhadda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shobha Dhadda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shobha Dhadda. The network helps show where Shobha Dhadda may publish in the future.

Co-authorship network of co-authors of Shobha Dhadda

This figure shows the co-authorship network connecting the top 25 collaborators of Shobha Dhadda. A scholar is included among the top collaborators of Shobha Dhadda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shobha Dhadda. Shobha Dhadda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Christopher, Sadao Katayama, Jae Hong Lee, et al.. (2025). Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease. The Journal of Prevention of Alzheimer s Disease. 12(5). 100160–100160. 9 indexed citations
2.
Devanarayan, Viswanath, Michael Donohue, Reisa A. Sperling, et al.. (2025). Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease. Alzheimer s & Dementia. 21(9). e70702–e70702. 2 indexed citations
3.
Devanarayan, Viswanath, Yuanqing Ye, Lü Tian, et al.. (2025). Predicted natural progression as an Alzheimer's prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency. Alzheimer s & Dementia. 21(3). e70045–e70045. 2 indexed citations
4.
Reyderman, Larisa, Natasha Penner, Arnaud Charil, et al.. (2025). Lecanemab Maintenance Dosing in Early Alzheimer’s Disease: Support for Continued Dosing from Clinical, Pharmacology, and Modeling Data (S23.007). Neurology. 104(7_Supplement_1).
5.
Wildsmith, Kristin R., Perminder S. Sachdev, Kanta Horie, et al.. (2024). Lecanemab Slows Amyloid‐Induced Tau Pathology as Supported by CSF MTBR‐tau243 in Clarity AD. Alzheimer s & Dementia. 20(S8). 2 indexed citations
6.
Devanarayan, Viswanath, T. Doherty, Arnaud Charil, et al.. (2024). Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer s & Dementia. 20(8). 5617–5628. 21 indexed citations
7.
Devanarayan, Viswanath, Daniel A. Llano, Yan Hu, et al.. (2024). Plasma pTau181 enhances the prediction of future clinical decline in amyloid‐positive mild cognitive impairment. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 16(3). e12621–e12621. 3 indexed citations
8.
Raman, Rema, Andy Liu, Oliver Langford, et al.. (2024). Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial. Alzheimer s & Dementia. 20(6). 3827–3838. 18 indexed citations
9.
Sperling, Reisa A., Shobha Dhadda, David Li, et al.. (2024). Is there Evidence for a Continued Benefit for Long‐Term Lecanemab Treatment? A Benefit/Risk Update from Long‐Term Efficacy, Safety and Biomarker Data. Alzheimer s & Dementia. 20(S6). 3 indexed citations
10.
Welsh‐Bohmer, Kathleen A., Geoffrey A. Kerchner, Shobha Dhadda, et al.. (2023). Decision making in clinical trials: Interim analyses, innovative design, and biomarkers. Alzheimer s & Dementia Translational Research & Clinical Interventions. 9(4). e12421–e12421. 1 indexed citations
11.
Sabbagh, Marwan N., Jeffrey L. Cummings, Steven M. Hersch, et al.. (2023). Isolated ARIA-H in patients treated with lecanemab in the phase 3 clarity AD study in early Alzheimer's disease. Journal of the Neurological Sciences. 455. 121401–121401. 1 indexed citations
12.
Cohen, Sarah, Christopher H. van Dyck, Michelle Gee, et al.. (2023). Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease. The Journal of Prevention of Alzheimer s Disease. 10(4). 771–777. 50 indexed citations
13.
Dyck, Christopher H. van, Chad J. Swanson, Paul Aisen, et al.. (2022). Lecanemab in Early Alzheimer’s Disease. New England Journal of Medicine. 388(1). 9–21. 2741 indexed citations breakdown →
14.
McDade, Eric, Jeffrey L. Cummings, Shobha Dhadda, et al.. (2022). Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimer s Research & Therapy. 14(1). 191–191. 185 indexed citations breakdown →
15.
Irizarry, Michael C., Shobha Dhadda, Michio Kanekiyo, et al.. (2021). Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. Alzheimer s & Dementia. 17(S9). 2 indexed citations
16.
17.
Swanson, Chad J., Yong Zhang, Shobha Dhadda, et al.. (2020). A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease. Alzheimer s & Dementia. 16(S9). 1 indexed citations
18.
Molinuevo, José Luís, Akihiko Koyama, Shobha Dhadda, et al.. (2019). DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY. Alzheimer s & Dementia. 15(7S_Part_28). 2 indexed citations
19.
Wang, Jinping, Veronika Logovinsky, Suzanne Hendrix, et al.. (2016). ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Journal of Neurology Neurosurgery & Psychiatry. 87(9). 993–999. 115 indexed citations
20.
Florman, Sander, Rita R. Alloway, Münci Kalayoğlu, et al.. (2007). Once-Daily Tacrolimus Extended Release Formulation: Experience at 2 Years Postconversion From a Prograf-Based Regimen in Stable Liver Transplant Recipients. Transplantation. 83(12). 1639–1642. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Larisa Reyderman Breakdown of academic impact, for papers by Craig Ritchie Breakdown of academic impact, for papers by Alina Solomon Breakdown of academic impact, for papers by Marwan Sabbagh Breakdown of academic impact, for papers by María M. Corrada Breakdown of academic impact, for papers by Alireza Atri Breakdown of academic impact, for papers by Maria Eriksdotter Breakdown of academic impact, for papers by Kate Zhong Breakdown of academic impact, for papers by Jean‐Marc Orgogozo Breakdown of academic impact, for papers by Lynn D. Kramer
Rankless by CCL
2026